BCN Peptides has been a key GAPVAC European Consortium member that has performed the first-in-human Clinical trial of a Personalized Therapeutic Vaccine to treat Glioblastoma. BCN Peptides role was the Manufacture of the GMP Peptide Library used for the Vaccine production. We are proud to announce that the demonstration of the proof-of-concept for the Personalized approach has been published by Nature on date 19th December, 2018 (https://www.nature.com/articles/s41586-018-0810-y/newly diagnosed glioblastoma | Nature ). For more information you can download the GAPVAC Press release. BCN Peptides is completely committed with the growth of Personalized Medicine, as we consider this is a strategic therapy for the treatment of oncology patients in the neaw future. For this reason we are actively developing solutions for the challenges that Individualized Drug production represents for the Pharma Industry. (http://gapvac.eu/nature-publication-reports-first-in-human-trial-of-a-novel-actively-personalized-therapeutic-vaccine-for-brain-cancer/)
Nature publication First-in-Human Personalized Therapeutic Vaccine for Brain Cancer.
December 20, 2018